Skip to main
MED
MED logo

Medifast (MED) Stock Forecast & Price Target

Medifast (MED) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 10%
Hold 60%
Sell 0%
Strong Sell 0%

Bulls say

Medifast Inc. has reported an encouraging increase in engagement metrics on its newly enhanced website, specifically highlighting a double-digit rise in average session time, which suggests growing interest in its products. The company is optimistic about potential improvement in sales per Coach in 4Q25 and anticipates a resumption of year-over-year growth in Coach numbers in the first half of 2026, fueled by signs of recovery in key underlying metrics. Additionally, Medifast has achieved significant cost savings and is poised for a projected sales growth of 6% year-over-year in 2026, reinforcing its commitment to delivering value to its stakeholders.

Bears say

Medifast Inc.'s financial outlook remains negative due to declining sales estimates, with a reduction in full-year sales projections to -21% year-over-year and a forecast of flat sales for the fourth quarter of 2025. The company's operating margin has significantly decreased to 0.6%, demonstrating a challenging cost structure amidst lower-than-expected return on investment and reduced advertising expenditures. Additionally, free cash flow has sharply decreased, projected at less than $30 million for 2024 compared to $138 million in 2023, raising concerns about financial sustainability without substantial cost-cutting measures implemented.

Medifast (MED) has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 10% recommend Buy, 60% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medifast and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medifast (MED) Forecast

Analysts have given Medifast (MED) a Buy based on their latest research and market trends.

According to 10 analysts, Medifast (MED) has a Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $77.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $77.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medifast (MED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.